Sign up for our newsletter and get the latest HPC news and analysis.
Send me information from insideHPC:

Czech supercomputers at IT4Innovations ready to combat coronavirus

The IT4Innovations National Supercomputing Center at VSB – Technical University of Ostrava has offered its users from academic institutions priority access to its computational resources to solve problems regarding COVID-19 disease research. “Today, we have called on our users to apply for our computational resources provided that they are currently involved in research addressing the COVID-19 disease,” said Vit Vondrak, IT4Innovations Managing Director. “Projects to be supported do not necessarily need to be focused only on drug design but could include development of nanomaterials or pandemic spread modeling among others.”

PolarisQB and Fujitsu Launch Drug Discovery Platform

Polarisqb has partnered with Fujitsu to create a ground-breaking drug discovery platform combining quantum-inspired technology, machine learning, hybrid quantum mechanics and molecular mechanics simulations (QM/MM). This new platform enables significantly faster, more cost-effective discovery of novel lead molecules to develop new drugs. Polarisqb and Fujitsu have begun a drug discovery project targeting Dengue Fever which has no approved treatments.

AiMOS Supercomputer at Rensselaer to Battle COVID-19

Rensselaer Polytechnic Institute is enlisting AiMOS, one of the most powerful supercomputers in the world, in the battle against the COVID-19 pandemic. Rensselaer is reaching out to the research community, including government entities, universities, and industry, to offer access to AiMOS in support of research related to the new coronavirus disease. “This effort requires expertise, collaboration, and the ability to process incredible amounts of data, and Rensselaer is offering all three at this critical time. In particular, the ability to model at very large scales requires the unique capabilities of AiMOS.”

IBM & DOE Launch COVID-19 High Performance Computing Consortium

Today, IBM, in collaboration with the DOE, launched the COVID-19 High Performance Computing Consortium. “The consortium bring together an unprecedented amount of supercomputing power—16 systems with more than 330 petaflops, 775,000 CPU cores, 34,000 GPUs, and counting—to help researchers everywhere tackle this global challenge. These high-performance computing systems allow researchers to run very large numbers of calculations in epidemiology, bioinformatics, and molecular modeling in hours or days, not weeks, months or years.”

Inspur Ranks in Top Three in 2019 IDC Global Server Market Report

According to IDC, Inspur ranked the top three vendors in global server revenue in 2019. Inspur was the only mainstream manufacturer in the world to maintain a double-digit growth, with an increase of 18.1% in sales and a market share of 7.0%. “Inspur has focused on the development of intelligent computing for many years, leading in the fields of AI, cloud data centers, open computing, and new data storage. With full-stack solution development capabilities in chips, boards, systems and software, Inspur is able to nimbly develop application-optimized custom computing solutions for users, and take advantage of the JDM (Joint Design Manufacturing) model to help Internet companies and large industry players remain competitive.”

AWS Diagnostic Development Initiative to fight COVID-19

Today Amazon launched the AWS Diagnostic Development Initiative, a program to support customers who are working to bring better, more accurate, diagnostics solutions to market faster and promote better collaboration across organizations that are working on similar problems. “Organizations working on diagnostics need reliable, scalable compute power, which we can deliver to them along with industry-leading services like analytics and machine learning, so they can process and analyze large data sets and iterate quickly.”

NVIDIA Gives COVID-19 Researchers Free Access Genome-sequencing software for GPUs

NVIDIA is offering COVID-19 Researchers free access to Parabricks genome-sequencing software for GPUs. “Starting today, NVIDIA will provide a free 90-day license to Parabricks to any researcher in the worldwide effort to fight the novel coronavirus. Based on the well-known Genome Analysis Toolkit, Parabricks uses GPUs to accelerate by as much as 50x the analysis of sequence data. We recognize this pandemic is evolving, so we’ll monitor the situation and extend the offer as needed.”

PSSC Labs Speeds HPC with AMD EPYC Processors

Today PSSC Labs touted impressive performance on their server lineup powered by AMD EPYC processors. Recently named an AMD Elite Partner, PSSC Labs is developing a unique set of platforms leveraging EPYC processors for AI, Big Data, HPC and IOT. In addition, these platforms will be optimized for computationally extensive workloads in the design & engineering, life science and weather modeling industries.

XSEDE Supercomputers Complete Simulations Pertinent to coronavirus, DNA Replication

Fundamental research supported by XSEDE supercomputers could help lead to new strategies and better technology that combats infectious and genetic diseases. “Chemical reactions, life, doesn’t happen that quickly,” Roston said. “It happens on a timescale of people talking to each other. Bridging this gap in timescale of many, many orders of magnitude requires many steps in your simulations. It very quickly becomes computationally intractable.”

AMD Powers Azure HBv2 Virtual Machines for HPC Workloads

The AMD and Microsoft partnership continues to expand this week with the launch of Microsoft Azure NVv4 Virtual Machines. Powered by 2nd Gen AMD EPYC  Processors and AMD Radeon Instinct GPUs, the powerful new VMs are now generally available to customers in South Central US, East US, and West Europe regions, with additional regions planned for the coming months. “These VMs, the first in the industry to be powered by both AMD EPYC CPUs and Radeon Instinct GPUs, enable customers to scale virtual desktops in the cloud that support a variety of workloads.”